What Should People Using Weight-Loss Injections Pay Attention To During A Check-Up?

Health monitoring for people using weight-loss injections does not consist solely of evaluating changes on the scale. Depending on the type of medicine used, existing conditions, medicines used at the same time, nutritional status and symptoms, blood glucose, kidney function, liver values, blood lipids and certain physical measurements may be monitored.

Medicines used for weight management, such as semaglutide and tirzepatide, may affect appetite, gastric emptying, the digestive system and blood glucose control. For this reason, regular monitoring during treatment is as important as the assessments performed at the beginning of treatment. However, there is no single standard test panel that applies to everyone using weight-loss injections. The necessary assessments should be determined by a physician according to the person’s health status.

Weight-loss injections are prescription medicines. Decisions to start, increase, reduce, interrupt or discontinue treatment should not be made by the person based solely on check-up results.

Why Does Weight-Loss Injection Use Require Regular Monitoring?

Injection treatments used for weight management are assessed together with a reduced-calorie dietary plan and physical activity suited to the individual. The goal of treatment is not only to achieve rapid weight loss but also to monitor the effects of weight loss on health, accompanying conditions and whether the medicine is being tolerated.

Digestive symptoms such as reduced appetite, nausea, constipation, diarrhoea or vomiting may occur during treatment. These symptoms may be mild and temporary, but in some people they may significantly affect food and fluid intake. Prolonged vomiting or diarrhoea in particular may lead to fluid loss and affect kidney function. Current semaglutide product information states that kidney function should be monitored in people experiencing adverse effects that may lead to fluid depletion.

Regular monitoring also helps determine whether the treatment contributes to the person’s initial goals, whether nutritional insufficiency has developed and whether there have been changes in the control of existing conditions.

Which Information Should Be Prepared Before The Check-Up?

For an accurate check-up assessment, details of the weight-loss injection and the treatment process should be shared with the physician. Medicines obtained from another institution, through a private prescription or from online channels may not appear in the person’s existing health records. The UK Medicines and Healthcare products Regulatory Agency also recommends asking patients whether they use GLP-1 or GLP-1/GIP medicines during assessment.

The following information may be prepared before the check-up:

• Brand name and active ingredient of the medicine

• Current dose and frequency of administration

• Treatment start date

• Date of the latest dose change

• Starting weight and current weight

• Weight change during recent weeks

• Other medicines and nutritional supplements being used

• History of diabetes, kidney disease, liver disease or gallstones

• Previous history of pancreatitis

• Thyroid disease and family history of thyroid cancer

• Possibility of pregnancy or plans for pregnancy

• Symptoms such as nausea, vomiting, diarrhoea, constipation and abdominal pain

• Changes in daily fluid and food intake

Recent blood test results, ultrasound reports and previous specialist assessments may also be brought to the check-up appointment. This may help avoid unnecessary repeat testing and make it easier to assess changes in results over time.

Which Physical Measurements May Be Assessed During A Check-Up?

Body weight should be monitored regularly in people using weight-loss injections. However, assessing treatment success only in kilograms is not sufficient. The rate of weight loss, waist circumference, blood pressure, muscle strength, daily functioning and changes in accompanying conditions should also be considered.

The following physical measurements may be assessed during a check-up:

• Body weight

• Height

• Body mass index

• Waist circumference

• Waist-to-height ratio

• Blood pressure

• Resting heart rate

• The course of weight change over time

The NICE follow-up checklist recommends assessing weight, waist circumference, body mass index and progress towards the person’s initial goals. However, the measurements required may differ according to the person’s clinical circumstances.

The possibility of muscle loss should also be considered in people experiencing rapid weight loss. If there is significant weakness, difficulty with everyday movements or reduced physical capacity, the nutritional and exercise plan may need to be reassessed.

Which Blood Tests May Be Performed While Using Weight-Loss Injections?

The same blood tests are not required for everyone using weight-loss injections. Test selection should be planned according to the person’s age, starting weight, existing conditions, medicines, symptoms and previous results.

The NICE initial assessment checklist states that blood pressure, lipids, HbA1c, blood glucose, kidney function, liver function, full blood count and thyroid function tests may be assessed depending on the person’s clinical circumstances.

Blood Glucose And HbA1c

Fasting blood glucose and HbA1c may need to be monitored in people with diabetes or prediabetes. The semaglutide product information recommends monitoring blood glucose before and during treatment in people with diabetes.

The risk of hypoglycaemia may increase particularly when the medicine is used together with insulin or certain other glucose-lowering medicines. The physician should be informed if the following symptoms occur:

• Shaking

• Cold sweating

• Sudden hunger

• Palpitations

• Dizziness

• Blurred vision

• Confusion or altered awareness

When blood glucose values fall, the doses of other diabetes medicines may need to be changed. However, this change should only be made by the physician managing the treatment.

Kidney Function And Electrolytes

Weight-loss injections do not directly cause kidney damage in every user. However, repeated vomiting, prolonged diarrhoea or insufficient fluid intake may result in dehydration. This may affect kidney function, particularly in people with pre-existing kidney disease.

When considered necessary, the physician may assess:

• Creatinine

• Estimated glomerular filtration rate

• Urea

• Sodium

• Potassium

• Other electrolytes

Current semaglutide product information recommends monitoring kidney function in people experiencing adverse effects that may lead to fluid depletion, particularly during treatment initiation or dose escalation.

A routine check-up appointment should not be awaited if there is a significant reduction in urine output, intense thirst, dry mouth, dizziness or an inability to consume fluids.

Liver Function And Blood Lipids

Overweight and obesity may occur together with metabolic conditions such as fatty liver disease, high cholesterol, elevated triglycerides and insulin resistance. Therefore, tests performed as part of a check-up aim to assess not only the possible effects of the medicine but also the person’s baseline metabolic risks.

Depending on the person’s health status, the following tests may be planned:

• ALT

• AST

• Gamma-glutamyl transferase

• Bilirubin

• Total cholesterol

• LDL cholesterol

• HDL cholesterol

• Triglycerides

A change in liver enzymes does not by itself mean that it was caused by the weight-loss injection. Fatty liver disease, alcohol consumption, other medicines, infections and different health conditions may also affect the results. The values should therefore be interpreted together with the person’s health history.

Full Blood Count And Nutritional Values

Reduced appetite while using a weight-loss injection may affect total food intake and dietary variety. Prolonged low energy intake, insufficient protein consumption or a highly restricted diet may contribute to certain nutritional deficiencies.

Nutritional status may be assessed separately when the following symptoms occur:

• Significant fatigue

• Muscle weakness

• Dizziness

• Paleness

• Marked hair loss

• Brittle nails

• Mouth ulcers

• Numbness or tingling

• Very rapid weight loss

Depending on the person’s symptoms and dietary habits, the physician may request a full blood count, ferritin, iron, vitamin B12, folate or vitamin D tests. These tests are not routinely required for everyone using weight-loss injections. The NICE follow-up checklist also recommends discussing concerns about inadequate micronutrient intake.

Thyroid Function Tests

Thyroid diseases may affect weight changes and metabolism. TSH and other thyroid tests considered necessary may therefore be assessed in people with a previous thyroid condition, those taking thyroid medicines or those experiencing symptoms suggestive of thyroid disease.

However, the benefit of routinely performing calcitonin tests or thyroid ultrasound in everyone using semaglutide is uncertain. Current product information states that the value of routine calcitonin monitoring or thyroid ultrasound for the early detection of medullary thyroid carcinoma is uncertain.

A medical assessment should be obtained if there is a lump in the neck, persistent hoarseness, difficulty swallowing or unexplained breathing difficulty.

What Should Be Considered Regarding The Gallbladder And Pancreas?

The characteristics of abdominal pain should be assessed carefully while using GLP-1- and GLP-1/GIP-based weight-management medicines. Not every abdominal pain indicates a serious condition, but severe, persistent pain that may radiate to the back may be a sign of acute pancreatitis.

On 29 January 2026, the UK Medicines and Healthcare products Regulatory Agency strengthened the product information for GLP-1 and GLP-1/GIP medicines regarding the risk of severe acute pancreatitis. The agency recommends urgent medical assessment for severe and persistent abdominal pain that may radiate to the back, particularly when accompanied by nausea and vomiting.

The following symptoms may occur with gallbladder problems:

• Pain in the upper-right part of the abdomen

• Pain that worsens after fatty meals

• Nausea or vomiting

• Fever

• Yellowing of the skin or eyes

• Dark urine

• Pale stools

When these symptoms occur, liver tests, bilirubin values or assessments such as ultrasound may be planned by a physician. It should not be assumed that everyone without symptoms requires routine pancreatic enzyme tests or abdominal ultrasound.

Should People With Diabetes Pay Attention To Eye Health?

People with type 2 diabetes and a history of diabetic retinopathy should state whether their eye examinations are up to date during the check-up. Semaglutide product information states that people with a history of diabetic retinopathy should be monitored for disease progression.

A routine appointment should not be awaited if the following symptoms occur:

• Sudden loss of vision

• Significant blurred vision

• New shadows in the visual field

• Flashes of light

• A curtain-like image in the visual field

Whether or not these symptoms are related to the weight-loss injection, they may require prompt ophthalmological assessment.

How Should Check-Up Results Be Interpreted?

Check-up results should not be interpreted according to a single laboratory value or only the amount of weight lost. The type of medicine, dose changes, rate of weight loss, dietary habits, fluid intake, existing conditions and other medicines should be considered together.

For example, a change in creatinine may not be caused only by the weight-loss injection. Vomiting, diarrhoea, insufficient fluid intake, blood pressure medicines or other kidney conditions may also affect the result. Similarly, liver enzymes should be assessed together with fatty liver disease, alcohol consumption, other medicines and the weight-loss process.

Normal check-up results also do not automatically mean that the medicine is suitable or that the current dose should continue unchanged. Treatment decisions should be made by considering the benefits of the medicine, adverse effects, the person’s goals and overall health.

How Is The Frequency Of Check-Ups Determined?

There is no fixed check-up interval that applies to everyone using weight-loss injections. The frequency of follow-up may differ according to the medicine used, dose-escalation periods, existing conditions, adverse effects and how well the treatment is tolerated.

Closer monitoring may be required at the beginning of treatment or after dose changes. If the medicine is well tolerated and health values remain stable, follow-up intervals may be rearranged by the physician. NICE follow-up recommendations also state that monitoring should be personalised according to adverse effects, accompanying conditions, other medicines, weight changes and the additional support required by the person.

Even when the person feels well, follow-up appointments recommended by the prescribing physician should not be missed.

Which Symptoms Should Not Wait Until The Check-Up?

Some symptoms experienced while using weight-loss injections may require medical assistance before the routine check-up.

The check-up date should not be awaited in the following situations:

• Severe and persistent abdominal pain

• Abdominal pain radiating to the back

• Repeated or persistent vomiting

• Inability to consume fluids

• Significant reduction in urine output

• Yellowing of the skin or eyes

• Fainting or altered consciousness

• Severe symptoms of hypoglycaemia

• Sudden loss of vision

• Swelling of the face, tongue or throat

• Significant shortness of breath

• Rapidly worsening general health

In cases of severe shortness of breath, altered consciousness, seizure, fainting or rapidly worsening general health, an online consultation or routine check-up should not be awaited. Emergency services should be contacted or the nearest emergency department should be visited.

This content is provided for general informational purposes. The selection, initiation, dose adjustment and discontinuation of a weight-loss injection require an individual medical assessment.

Plan Your Online Endocrinology Doctor Consultation With Happ Health

With the “Health Everywhere, For Everyone, Always.” approach, we believe that weight-loss injection treatment should be managed not only by issuing a prescription but also through a safe initial assessment and a regular follow-up plan.

By planning an Online Endocrinology Doctor consultation through Happ Health, you can have your weight history, medical history, medicines, existing test results and suitability for treatment assessed. An endocrinologist may determine which tests are required according to your individual risks and provide guidance on medicines, nutrition, physical activity or a different treatment approach based on the results.

Preparing your recent test results, a list of the medicines you use, previous weight-loss treatments and any available ultrasound or imaging reports before the online consultation may make the assessment easier. When a physical examination or additional tests are needed, you may be referred to an in-person healthcare institution.

In cases of severe and persistent abdominal pain, repeated vomiting, inability to consume fluids, fainting, jaundice or rapidly worsening general health, an online follow-up should not be awaited and a healthcare institution should be contacted.

References

• National Institute for Health and Care Excellence, Initial Assessment Before Prescribing Tirzepatide Checklist:
  https://www.nice.org.uk/guidance/ta1026/resources/initial-assessment-before-prescribing-tirzepatide-checklist-msword-15299629885

• National Institute for Health and Care Excellence, Follow-Up And Monitoring When Prescribing Tirzepatide Checklist:
  https://www.nice.org.uk/guidance/ta1026/resources/follow-up-and-monitoring-when-prescribing-tirzepatide-checklist-msword-15299629887

• National Institute for Health and Care Excellence, A Practical Guide To Using Medicines To Manage Overweight And Obesity:
  https://www.nice.org.uk/guidance/ta1026/resources/a-practical-guide-to-using-medicines-to-manage-overweight-and-obesity-15299628589/chapter/Prescribing-reviewing-and-stopping-tirzepatide

• U.S. Food and Drug Administration, Current Wegovy Prescribing Information:
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf

• U.S. Food and Drug Administration, Current Zepbound Prescribing Information:
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf

• Medicines and Healthcare products Regulatory Agency, GLP-1 Medicines And Acute Pancreatitis Safety Warning:
  https://www.gov.uk/drug-safety-update/glp-1-receptor-agonists-and-dual-glp-1-slash-gip-receptor-agonists-strengthened-warnings-on-acute-pancreatitis-including-necrotising-and-fatal-cases